Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02253875
Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT02253862
Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 52
- Registration Number
- NCT02251795
Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251171
Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251769
The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251119
Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 81
- Registration Number
- NCT02248883
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 72
- Registration Number
- NCT02246998
Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02245451
Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT02245269
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath